Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Cholangiocarcinoma: novel therapeutic targets.

Expert opinion on therapeutic targets - 1 Apr 2020

Sato Keisaku, Glaser Shannon, Alvaro Domenico, Meng Fanyin, Francis Heather, Alpini Gianfranco

Abstract excerpt

Introduction: Cholangiocarcinoma (CCA) is a liver cancer derived from the biliary tree with a less than 30% five-year survival rate. Early diagnosis of CCA is challenging and treatment options are limited. Some CCA patients have genetic mutations and several therapeutic drugs or antibodies have been introduced to target abnormally expressed proteins. However, CCA is heterogeneous and patients often present with...

Topics

Join the communities discussing this publication.

Bile Duct Neoplasms
Antineoplastic Agents
Cholangiocarcinoma
Disease Progression
Drug Development

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Drug Resistance, Neoplasm

Molecular Targeted Therapy

Tumor Microenvironment

Source

Open in PubMed Open full text

Identifiers

PMID: 32077341
DOI: 10.1080/14728222.2020.1733528
PMCID: PMC7129482

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 1 Sept 2026.

Community interpretation

Discuss the evidence

Ask a question, add context or challenge an interpretation. Community activity is separate from scientific evidence strength.

0

discussions

0

replies

Citations encouraged

Claims remain attributable.

No discussion yet

Be the first to add a careful, cited interpretation.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Cholangiocarcinoma: novel therapeutic targets.PMID 32077341Read ↗

Therapy for advanced cholangiocarcinoma: Current knowledge and future potential.Semantic proximity Read ↗

Molecular mechanisms and genetic features of cholangiocarcinoma: implications for targeted therapeutic strategiesSemantic proximity Read ↗

Molecular Pathogenesis of Cholangiocarcinoma: Implications for Disease Classification and Therapy.Semantic proximity Read ↗

Intrahepatic cholangiocarcinoma: current management and emerging therapies.Semantic proximity Read ↗

Pathogenesis of CholangiocarcinomaSemantic proximity Read ↗

Molecular biology of cholangiocarcinoma and its implications for targeted therapy in patient management.Semantic proximity Read ↗

Evolution of Treatment in Advanced Cholangiocarcinoma: Old and New towards Precision Oncology.Semantic proximity Read ↗

Signalling networks in cholangiocarcinoma: Molecular pathogenesis, targeted therapies and drug resistanceSemantic proximity Read ↗

Targeting cholangiocarcinoma.Semantic proximity Read ↗

Update on cholangiocarcinoma: potential impact of genomic studies on clinical management.Semantic proximity Read ↗

Developments in FGFR and IDH inhibitors for cholangiocarcinoma therapy.Semantic proximity Read ↗

Cholangiocarcinoma: new perspectives for new horizonsSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.